

The Long-Lasting Persistence of SARS-CoV-2 Nucleic Acid in COVID-19 Patients

Shan Li

Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital
<https://orcid.org/0000-0003-4330-6280>

Chaojie Wu

Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Mingshun Zhang

Nanjing Medical University

Lianzheng Zhou

Changzhou No.2 People's Hospital

Jie Xiang

Wuhan Jinyintan Hospital

Wei Zhang

Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Yuan Ma

Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Wenqiu Ding

Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Zhengxia Wang

Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Mao Huang

Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Ningfei Ji (✉ jiningfei@163.com)

Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Case Report

Keywords: SARS-CoV-2, COVID-19, Convalescent, Nucleic acid test, Long-lasting

Posted Date: March 31st, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-354369/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **The long-lasting persistence of SARS-CoV-2 nucleic acid in**
2 **COVID-19 patients**

3 Shan Li^{1*}, Chaojie Wu^{1*}, Mingshun Zhang², Lianzheng Zhou³, Jie Xiang^{4,5},
4 Wei Zhang⁶, Yuan Ma¹, Wenqiu Ding¹, Zhengxia Wang¹, Mao Huang^{1¶},
5 Ningfei Ji^{1¶}

6 ¶ Correspondence to: Mao Huang, hm6114@163.com; Ningfei Ji,
7 jiningfei@163.com;

8 * Contribute equally

9

10 **Abstract**

11 **Background:**

12 Although recurring cases of COVID-19 have been sporadically reported, the
13 long-persistence of severe acute respiratory syndrome coronavirus 2
14 (SARS-CoV-2) is still arguable. We aimed to provide the evidences of
15 recovered COVID-19 patients with long-lasting positive SARS-CoV-2 RNA
16 tests in a Chinese hospital.

17 **Case presentations:**

18 We reported 4 discharged patients with COVID-19 patients relapsed during the
19 period of self-quarantine, leading to an extended disease course. All of four
20 patients were historically healthy without known underlying diseases (diabetes,
21 hypertension, cancer, i.e.) which may influence the disease course.

22 **Conclusion:**

23 The persistent course of SARS-COV-2 nucleic acid test positive in these 4
24 cases was prolonged, which provided some ideas for the long-term existence

25 of SARS-COV-2 RNA in convalescent patients.

26 **Keywords:**

27 SARS-CoV-2; COVID-19; Convalescent; Nucleic acid test; Long-lasting

28 **Background**

29 The current pandemic of COVID-19 which caused by a novel coronavirus
30 (SARS-CoV-2) is unprecedented. It has exhibited distinctive features from prior
31 coronavirus related diseases. Compared with SARS and MERS, COVID-19
32 shows higher infectivity [1]. What's more, it is concerned that the global
33 epidemic situation of COVID-19 has not been effectively controlled currently.

34 With effective prevention and control in China, the number of discharged
35 cases has increased significantly. Recently, during the follow-up of discharged
36 patients, cases with repeated positive nucleic acid tests have been reported
37 sporadically[2-5], which draw people's attention to the discharged COVID-19
38 patients. The explanation for this phenomenon is inconclusive currently, it
39 raises the concern that discharged COVID-19 patients may be at risk of viral
40 reactivation and be considered potential transmission of SARS-CoV-2
41 infection.

42 Some previous research of COVID-19 discharged patients nucleic acid
43 re-positive lasted within 2 months[6-8], presently, the persistent course of the 4
44 cases we are about to show lasts more than 3 months. This may provide an
45 idea for long- lasting positive SARS-CoV-2 RNA tests in recovered COVID-19
46 patients.

47 **Case presentations**

48 **Case 1** A 35-year-old man with a history of COVID-19 contact presented
49 with cough, fever and short of breath. With ground glass opacities (GGO) chest

50 computed tomography (CT), he was clinically diagnosed with common
51 COVID-19. After 28 days supportive treatment and complete symptoms relief,
52 he was discharged from the hospital and quarantined in a hotel. In the hotel,
53 his throat swab test was positive for SARS-CoV-2 (Day 54 from disease onset).
54 And the asymptomatic patient was readmitted into the hospital. With full
55 supportive therapy, the patient was still positive for SARS-CoV-2 in throat swab
56 and sputum on day 70, day 76, and day 92. He was positive for SARS-CoV-2
57 IgM and IgG (Day 76). On day 93 and 94, he turned negative for SARS-CoV-2
58 and was discharged from the hospital. SARS-CoV-2 infection lasted at least 92
59 days in patient #1.

60 **Case 2** A 64-year-old woman with a history of COVID-19 contact
61 presented with fever and fatigue. Without significant improvement in private
62 clinic, she was admitted into the hospital. Her throat swab test was positive
63 (Day 33 from disease onset) and she was diagnosed with common COVID-19.
64 With supportive therapy, her symptoms were relieved and pulmonary GGO
65 was almost absorbed (Day 53). The patient was discharged. However, she
66 was tested positive again in throat swab (Day 64). After the re-admission into
67 hospital, the patient was asymptomatic but positive for SARS-CoV-2 nucleic
68 acid and IgG, negative for SARS-Cov-2 IgM (Day 67). PCR test in throat swab
69 was still positive in Day 90. On day 91 and 92, the repeated SARS-CoV-2
70 nucleic acid tests were negative. She was discharged from the hospital.
71 SARS-CoV-2 lasted at least 90 days in patient #2.

72 **Case 3** A 56-year-old woman presented with fever, chest tightness, short
73 of breath and chest X-ray showing pneumonia. Her throat swab test was
74 positive (Day 14 from disease onset) and she was diagnosed with common

75 COVID-19. With supportive therapy, her symptoms disappeared and
76 pulmonary GGO was largely absorbed (Day 33). After 13 days from her
77 discharge, her throat swab test was positive and re-admitted into the hospital
78 (Day 46). She was empirically treated and discharged again from the hospital
79 (Day 65) after the nucleic acid tests turned negative. During the self-quarantine,
80 she was again positive in throat swab test and re-re-admitted into the hospital
81 (Day 81). She was without evident symptoms. The patient was positive for
82 SARS-CoV-2 specific IgG but negative for SARS-CoV-2 specific IgM. At Day
83 92, she was still positive in throat swab nucleic acid test but negative in blood
84 and feces nucleic acid tests. In the repeated nucleic acid tests in different
85 samples at Day 93/94, she was negative. Therefore, the patient was
86 discharged at Day 95. SARS-CoV-2 persisted at least 92 days in patient #3.

87 **Case 4** A 60-year-old man with a history of COVID-19 contact presented
88 with fatigue, fever and dyspnea. Chest CT showed GGO and he was
89 diagnosed with severe COVID-19 (Day 9). With empirical therapy, he was
90 relieved and self-quarantined in home. In the community test, his throat swab
91 test was positive and re-admitted into the hospital (Day 25). With supportive
92 therapy, his nucleic acid tests were still repeatedly positive (Day 52). And the
93 patient was given thymalfasin to boost the immune system. At Day 60, he was
94 discharged with negative nucleic acid tests. During the isolation, the patient
95 turned repeatedly positive for SARS-CoV-2 nucleic acid (Day 72). He was
96 re-re-admitted into the hospital. He complained cough, sputum production, and
97 chest tightness. Chest CT showed interstitial pneumonia. Sera tests indicated
98 the patient was positive for SARS-CoV-2 IgG but negative for virus specific IgM.
99 With full supportive therapy, his nucleic acid tests finally turned negative at Day

100 109. And the patient was discharged at Day 111. SARS-CoV-2 persisted at
101 least 108 days in patient #4.

102 **Discussion**

103 The estimated time for COVID-19 varied, ranging from 15.6 days to 49.4
104 days[9]. In the present study, we reported 4 cases of COVID-19 with
105 extended disease duration.

106 As the main entry route, pulmonary involvement was the main
107 manifestation in patients with COVID-19. An autopsy pathological study of a
108 ready-for discharge COVID-19 patient who succumbed to sudden
109 cardiovascular accident revealed that SARS-CoV-2 remained in lung cells
110 and caused lung lesions[10]. Chest X-ray maybe not as sensitive as CT to
111 detect small but significant pulmonary exudates; thereby some patients with
112 COVID-19 may be prematurely released before the full and true recovery.

113 The second explanation for the early discharge was that the RT-PCR test
114 may be false negative[6, 7]. Repeated tests in different samples before the
115 discharge may decrease the risk of false negative results. In our study,
116 RT-PCR tests were positive in sputum and throat swab but negative in blood,
117 anal swabs or feces, which was different from other reports[11, 12]. We
118 recommended testing multi-site specimen for virus surveillance in the
119 re-admitted patients. The third but less likely cause for RT-PCR test positive
120 results was due to the re-infection. There is still no direct evidence that
121 recovered COVID-19 patients autonomously acquire complete immunity

122 against SARS-CoV-2. In the present study, however, all patients with
123 COVID-19 were quarantined, significantly reducing the risk of re-exposure to
124 SARS-CoV-2.

125 The RT-PCR test positive results in the discharged patients with COVID-19
126 may be from the true virus or less likely from virus fragments. In the 4 patients
127 with extended duration of COVID-19, 3 patients were positive for
128 SARS-CoV-2 specific IgG. In theory, the virus hidden in the body[10] may
129 escape from the immune responses by mutation, which would increase the
130 risk of re-emergence of new serotype of SARS-CoV-2 in future. In a recent
131 study[8], RT-PCR of pharyngeal swabs and IgM/IgG antibodies against
132 SARS-CoV-2 were negative for close contacts of discharged COVID-19
133 patients, they hold on prolonged presence of viral nucleic acid in clinically
134 recovered COVID-19 patients was no associated with effective infectiousness.
135 Besides, a recent study describe evidence that SARS-CoV-2 RNA
136 reverse-transcribed and integrated into the human genome[13], however, the
137 result is controversial currently.

138 This study is hampered by some limitations. First, whether the re-admitted
139 patients with COVID-19 were asymptomatic virus carrier[14] was not answered.
140 Though virus may be hardly isolated in the late samples[15], virus culture
141 should be explored to test the infectivity of RT-PCR positive respiratory
142 samples. Second, the potential causes for the RT-PCR test positive results in
143 recovered COVID-19 patients were unexplored. Third, the disease course of

144 COVID-19 in these patients may still develop. We should keep following
145 these patients and better understand the disease course of COVID-19.
146 SARS-CoV-2 persistence in the asymptomatic populations would pose new
147 challenges to global COVID-19 prevention and control strategies.

148 **Conclusion**

149 In summary, we showed that the persistent course of SARS-COV-2 nucleic
150 acid test positive in these 4 cases was prolonged, which provided some ideas
151 for the long-term existence of SARS-COV-2 RNA in convalescent patients.

152 **List of abbreviations**

153 SARS-CoV2: Severe acute respiratory syndrome coronavirus 2; COVID-19:
154 Coronavirus disease 2019; RT-PCR: Reverse transcription-polymerase chain
155 reaction; IgM: Immunoglobulin M; IgG: Immunoglobulin G.

156 **Acknowledgments**

157 Not applicable.

158 **Authors' contributions**

159 NJ and MH had the idea for and designed the study and had full access to all
160 of the data in the study and take responsibility for the integrity of the data and
161 the accuracy of the data analysis. SL, CW, MZ, LZ, JX, WZ, YM, WD, and ZW
162 collected the data. NJ, SL and CW analyzed the data and drafted the paper.
163 All authors agree to be accountable for all aspects of the work in ensuring that
164 questions related to the accuracy or integrity of any part of the work are
165 appropriately investigated and resolved.

166 **Funding**

167 This study was funded by the Jiangsu Provincial Key Research and
168 Development Program (BE2020616). We thank all patients involved in the
169 study.

170 **Availability of data and materials**

171 The datasets used during the current study are available from the
172 corresponding author on reasonable request.

173 **Ethics approval and consent to participate**

174 This study was conducted in accordance with the ethical committee of The
175 First Affiliated Hospital of Nanjing Medical University (approval number
176 2020-SR-120).

177 **Consent for publication**

178 Written consent was obtained from the patients for publication.

179 **Competing interests**

180 All authors declare no conflict of interest.

181 **Author details**

182 ¹Department of Respiratory and Critical Care Medicine, The First Affiliated
183 Hospital of Nanjing Medical University, Nanjing 210029, China

184 ²Key Laboratory of Antibody Techniques of National Health Commission,
185 Department of Immunology, Nanjing Medical University, Nanjing 211166,
186 China

187 ³Department of Respiratory and Critical Care Medicine, The Affiliated
188 Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou

189 213003, China

190 ⁴Diagnosis and Treatment Research Center of Wuhan Infectious Disease of
191 Chinese Academy of Medical Sciences, Wuhan 430023, China

192 ⁵Department of laboratory, Wuhan Jinyintan Hospital, Wuhan 430024, China

193 ⁶Department of Radiology, The First Affiliated Hospital of Nanjing Medical
194 University, Nanjing 210029, China

195 Reference

- 196 1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease
197 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center
198 for Disease Control and Prevention. *JAMA*.2020 2020-04-07;323(13):1239-42.
- 199 2. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR Test Results in Patients
200 Recovered From COVID-19. *JAMA*.2020 2020-04-21;323(15):1502-3.
- 201 3. Xing Y, Mo P, Xiao Y, Zhao O, Zhang Y, Wang F. Post-discharge surveillance and positive virus
202 detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January
203 to February 2020. *Euro Surveill*.2020 2020-03-01;25(10).
- 204 4. Qu YM, Kang EM, Cong HY. Positive result of Sars-Cov-2 in sputum from a cured patient with
205 COVID-19. *Travel Med Infect Dis*.2020 2020-03-01;34:101619.
- 206 5. Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, et al. Recurrence of positive SARS-CoV-2 RNA in
207 COVID-19: A case report. *INT J INFECT DIS*.2020;93:297-9.
- 208 6. Xiao AT, Tong YX, Zhang S. False negative of RT-PCR and prolonged nucleic acid conversion
209 in COVID-19: Rather than recurrence. *J MED VIROL*.2020 2020-10-01;92(10):1755-6.
- 210 7. Li Y, Hu Y, Yu Y, Zhang X, Li B, Wu J, et al. Positive result of Sars-Cov-2 in faeces and sputum
211 from discharged patients with COVID-19 in Yiwu, China. *J MED VIROL*.2020
212 2020-10-01;92(10):1938-47.
- 213 8. Hong K, Cao W, Liu Z, Lin L, Zhou X, Zeng Y, et al. Prolonged presence of viral nucleic acid in
214 clinically recovered COVID-19 patients was not associated with effective infectiousness. *Emerg*
215 *Microbes Infect*.2020 2020-12-01;9(1):2315-21.
- 216 9. Sun J, Xiao J, Sun R, Tang X, Liang C, Lin H, et al. Prolonged Persistence of SARS-CoV-2 RNA
217 in Body Fluids. *EMERG INFECT DIS*.2020 2020-08-01;26(8):1834-8.
- 218 10. Yao XH, He ZC, Li TY, Zhang HR, Wang Y, Mou H, et al. Pathological evidence for residual
219 SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient. *CELL RES*.2020
220 2020-06-01;30(6):541-3.
- 221 11. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Persistence and clearance of viral RNA
222 in 2019 novel coronavirus disease rehabilitation patients. *Chin Med J (Engl)*.2020
223 2020-05-05;133(9):1039-43.
- 224 12. Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X, et al. Prolonged presence of SARS-CoV-2 viral
225 RNA in faecal samples. *Lancet Gastroenterol Hepatol*.2020 2020-05-01;5(5):434-5.

- 226 13. Zhang L, Richards A, Khalil A, Wogram E, Ma H, Young RA, et al. SARS-CoV-2 RNA
227 reverse-transcribed and integrated into the human genome. bioRxiv.2020 2020-12-13.
- 228 14. Zhang J, Du Y, Bai L, Pu J, Jin C, Yang J, et al. An Asymptomatic Patient with COVID-19. Am J
229 Respir Crit Care Med.2020 2020-06-01;201(11):1428-9.
- 230 15. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. Virological
231 assessment of hospitalized patients with COVID-2019. NATURE.2020 2020-05-01;581(7809):465-9.
- 232